Consumer longevity company partners with wellness firms to advance personalized, preventive solutions for healthy aging.
Consumer longevity biotech Tally Health has announced two new partnerships focused on advancing personalized approaches to managing aging. The strategic collaborations – with performance health company Cenegenics and functional fitness brand Pvolve – seek to integrate Tally’s epigenetic science with lifestyle-based wellness strategies to drive healthspan improvements.
Co-founded by leading aging researcher Dr David Sinclair, Tally combines repeated epigenetic age testing with individualized interventions aimed at improving biological age and enabling a more informed, proactive approach to aging.
“At Tally Health, we believe the future of longevity lies at the intersection of science, expert care, and daily action,” Tally Health CEO Melanie Goldey told us. “Our partnerships with Cenegenics and Pvolve reflect a shared commitment to redefining what healthy aging looks like – by meeting people where they are with personalized, preventive solutions that adapt to their unique biology and goals.”
Today, Tally announced its partnership with Pvolve, a fitness company that has developed a clinically-backed workout method emphasizing strength, stability and mobility. This came hot on the heels on news of the company’s collaboration with Cenegenics, a specialist in precision health and performance optimization.
Together with Pvolve, Tally has developed the Longevity Formula Program, a premium, bundled offering that combines epigenetic insights and nutritional interventions with Pvolve’s functional movement system. The program includes six months of access to Tally’s complete supplement protocol, two epigenetic tests to track biological aging, and a comprehensive digital fitness membership that provides access to more than 1,500 classes, personalized training and virtual studio sessions. Participants also receive a suite of Pvolve’s performance-enhancing equipment and individualized support through private sessions with both Pvolve trainers and Tally scientists.
“Longevity is more than just adding years to your life,” said Rachel Katzman, founder of Pvolve. “It’s about making those years vibrant and fulfilling. This partnership brings together two powerful approaches – Tally Health’s cutting-edge longevity science and Pvolve’s results-driven movement – to help people feel their best from the inside out. This is preventative health reimagined. It is comprehensive, personalized, and rooted in science.”
The Cenegenics partnership brings Tally’s epigenetic testing and science-backed supplements into Cenegenics’ nationwide network of physician-led centers. Central to the collaboration is the integration of Tally’s next-generation biological aging clock that evaluates over 200,000 DNA methylation sites via a simple cheek swab. Trained on the world’s largest dataset of its kind, the test is designed for accuracy, reproducibility and inclusivity, capturing a diverse population to better reflect biological variability.
Earlier this year, a peer-reviewed study in the journal GeroScience highlighted the associations between Tally’s epigenetic aging clock and a variety of diseases and conditions. The study analyzed 25 publicly available DNA methylation datasets, revealing significant correlations between the company’s clock and 33 different health and disease variables.
Cenegenics patients will now be able to incorporate this tool into their existing care programs, enabling them to track changes in their biological age and make more informed decisions about interventions.
“Our collaboration with Tally Health brings cutting-edge epigenetic testing and science-backed longevity supplements into our program, empowering us to further personalize care and track biological aging in a meaningful way,” said Cenegenics CEO Kristy Berry. “This partnership strengthens our mission to help patients not just extend their lifespan, but enhance their quality of life at every stage.”
Additionally, Tally Health’s line of pro-longevity supplements, formulated to support mitochondrial function, cellular health and energy metabolism, will become part of Cenegenics’ therapeutic offerings. The partnership also includes a joint research initiative to measure and validate the effects of interventions through real-world data.
“Whether it’s through Cenegenics’ precision medical expertise or Pvolve’s science-backed movement method, we’re expanding access to transformative tools that help people not just live longer, but live better – staying vibrant, strong, and energized for decades to come,” Goldey told us.
Photographs courtesy of Tally Health.
The post Tally Health teams up with Pvolve and Cenegenics appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
